

Immune Checkpoint Inhibitors: Response Rates in Solid Tumors

Indication	Anti-PD-1 Overall Response Rate (ORR)	Anti-PD-1 + Anti-CTLA-4 ORR	Trial
Melanoma	40%	50%	CHECKMATE-067 ¹
MSI-H CRC*	28%	46%	CHECKMATE-142 ¹
SCLC**	11%	23%	CHECKMATE-032 ²
RCC***	21.5% (2L)	41.6% (1L)	CHECKMATE-025 (2L) ¹ CHECKMATE-214 (1L) ¹

* Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

** Small Cell Lung Cancer

*** Renal Cell Carcinoma

References:

1. [OPDIVO \[package insert\]](#) Princeton, NJ: Bristol-Myers Squibb Company. Accessed July 11, 2018.
2. Checkmate-032 (Hellmann, J Thorac Oncol, Vol. 12, Issue 1, S393 - S394)